{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "MATV",
  "name": "Mativ Holdings, Inc.",
  "url": "https://orbyd.app/dossiers/MATV/",
  "json_url": "https://orbyd.app/dossiers/MATV.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Post-divestiture Mativ is being repriced as a self-help deleveraging story: the 2026-08-05 Q2 print delivered record adj EBITDA of $75.0M at a 14.1% margin and cut net leverage to 3.8x on $60.4M of free cash flow, and shares gapped +9.2%. The leg is fresh in attention and stretched in price — RSI(14) 92.0 at the 2026-08-07 close of $12.89, with no dated catalyst before the ~November Q3 report.",
  "invalidation_trigger": "A weekly close below $11.50 gives back the 2026-08-05 earnings gap and returns price to the pre-print range; secondarily, a Q3 report (~2026-11-05, est.) showing adjusted EBITDA margin back under 13% or net debt failing to fall from $908.2M would break the deleveraging leg.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "cyclical-industrials"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Two-segment company since the $620M Engineered Papers sale to Evergreen Hill Enterprise (gain on sale $176.3M); pre-2024 financial history is not a clean comp.",
    "No full-year 2026 outlook was provided in the 2026-08-05 Q2 release, so consensus is unanchored by company guidance.",
    "Sell-side coverage is thin and aggregator-published price targets span a wide range, from roughly $10 to $21.",
    "Balance sheet at 2026-06-30: $974.5M total debt, $66.3M cash, $908.2M net debt, 3.8x net leverage — a levered small-cap equity."
  ],
  "body_markdown": "## Current Thesis\nMativ is being repriced on self-help, not demand. The 2026-08-05 second-quarter report showed adjusted EBITDA of $75.0M (+12% YoY) at a 14.1% margin (+130bps) on net sales of $531.8M that grew 1.2% reported and 1.7% organic. Free cash flow of $60.4M (+24%) cut net debt $61M sequentially to $908.2M and net leverage to 3.8x. Shares rose 9.2% on the print.\n\nThe narrative leg on offer is a levered-equity deleveraging story: with $974.5M of total debt against $66.3M of cash at 2026-06-30, an incremental turn of EBITDA or a year of $60M-quarters of cash generation lands disproportionately on a small equity base. That is the whole bid. Volume is not carrying it — organic growth is under 2% and the higher-margin Filtration & Advanced Materials segment shrank 1.3% reported.\n\nWhat complicates a fresh look is the entry point, not the arithmetic. RSI(14) printed 92.0 at the 2026-08-07 close of $12.89, the three-month return is +41.3%, and the catalyst that produced the move has already occurred. The next company-dated event of consequence is the Q3 report, roughly three months away.\n\n## Bull Case\n- Q2 2026 adjusted EBITDA $75.0M, +12% YoY, margin 14.1% (+130bps) — management described it on the 2026-08-05 call as the strongest quarter since Mativ was formed four years ago.\n- Sustainable & Adhesive Solutions, the larger segment, is where the improvement sits: sales $330.1M (+2.8%) with adjusted EBITDA margin of 15.3%, up 210bps YoY (2026-08-05 release).\n- Filtration & Advanced Materials held margin at 17.6% (+50bps) on sales of $201.7M despite flat organic volume — cost actions are carrying a segment with no top-line help.\n- Cash conversion is real for now: free cash flow $60.4M (+24% YoY), net debt down $61M QoQ to $908.2M, net leverage 3.8x at 2026-06-30, total liquidity $345.5M.\n- GAAP income swung positive to $3.6M from a $9.5M loss in the year-ago quarter — the reported line no longer needs an adjustment bridge to show black ink.\n- Capital return was maintained alongside paydown: $0.10 per share declared, payable 2026-09-25.\n- Adjusted EPS of $0.50 cleared the consensus figures cited by wire services on the day — $0.28 (Benzinga) and $0.34 (AP snapshot) — a gap wide enough that the sell-side model set is plainly stale.\n\n## Bear Case\n- The growth is not there. Reported sales +1.2%, organic +1.7%, and FAM organic −0.1% in Q2 2026. A margin-only story compounds until the cost program runs out of runway.\n- The 2026-08-05 release carried no full-year 2026 outlook. Without a company-set bar, the next print is graded against a thin, dispersed analyst set — and beat size depends on which consensus a reader uses.\n- Free cash flow was helped by timing. On the Q2 call, management attributed the improvement partly to lower restructuring spend and capital-expenditure timing, which makes $60.4M a poor run-rate anchor for H2.\n- Leverage remains high in absolute terms: 3.8x net, $908.2M net debt against roughly $75M of quarterly adjusted EBITDA. Deleveraging at this pace is a multi-year project, and a demand air-pocket reverses the ratio faster than cash pays it down.\n- Price has already discounted a good deal of this. RSI(14) 92.0 at 2026-08-07 is a top-decile stretch reading, and at $12.89 the stock is still 12.4% below the 52-week high of $14.72 — it is climbing back into a year's worth of overhead supply from holders who bought higher.\n- Sell-side coverage is thin, and aggregator-published targets span a wide range (one screen shows a $10 target, another a $21 high). Sparse coverage means little institutional anchoring under a gap.\n\n## Setup & Price Structure\n- Last completed daily close $12.89 (2026-08-07); 52-week high $14.72; distance from high −12.4%; three-month return +41.3%; RSI(14) 92.0.\n- The structure is a recovery rally into prior supply, without a breakout to new highs. $14.72 is the measurable objective and the first hard resistance the tape has to prove against.\n- The 2026-08-05 earnings gap is the load-bearing structure. Price holding above the post-print shelf keeps the re-rate intact; a weekly close below $11.50 returns the stock into the pre-print range and makes the August move a fade.\n- Life-cycle: **ACCELERATING**, dated to the 2026-08-05 print (+9.2% on the day) and the +41.3% three-month run through 2026-08-07. The qualifier is participation — thin analyst coverage and wide aggregator target dispersion suggest the bid is narrow rather than broad.\n- Crowding and positioning observables, stated as observables: RSI(14) at 92.0 is an extreme momentum reading; the earnings catalyst is behind the tape, not ahead of it (2026-08-05), so nothing dated forces a repricing inside 30 days; no Form 4 insider transactions appear in the recent filing record reviewed for this note; no equity issuance into the strength has been disclosed since the print.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-08-14 (est.)** — Q2 2026 Form 10-Q, due inside the standard quarterly-report window after the 2026-06-30 period end. The detail that matters: capex line versus the FCF beat, debt maturity schedule, and the reported-versus-organic bridge (reported +1.2% against organic +1.7%).\n- **2026-09-25** — declared dividend of $0.10 per share payable; record date was not disclosed in the 2026-08-05 release. Outside the strict 30-day window, listed because it is the only other confirmed company date on the calendar.\n- **~2026-11-05 (est.)** — Q3 2026 results, based on the 2026-05-08 (Q1) and 2026-08-05 (Q2) cadence. This is the first test of whether 14.1% adjusted EBITDA margin and sub-3.8x leverage are a level or a peak.\n- No confirmed regulatory, product or capital-markets event is scheduled inside the next 30 days.\n\n## What Would Change Our Mind\nThe structure that breaks first is the August gap. If the post-print shelf goes, the fundamental case has not changed but the market's willingness to pay for it has, and the RSI 92.0 reading at 2026-08-07 says there is little cushion under the move. The gradeable version: a weekly close below $11.50 ends the re-rate leg and puts price back in the pre-earnings range.\n\nOn fundamentals, the thesis breaks at the ~2026-11-05 Q3 print if adjusted EBITDA margin falls back below 13% or net debt fails to decline from $908.2M — either would show the Q2 margin and cash performance was a timing artifact rather than a level. A capex step-up in the 10-Q large enough to explain most of the $60.4M free-cash-flow figure would do the same work earlier.\n\nThe read also weakens without a price break if the story turns SATURATED — broad sell-side initiations and retail-sentiment coverage clustering around a name that has already run 41% in three months would mean the marginal buyer has arrived.\n\n## Correlation Notes\n- Levered small-cap credit beta: with $974.5M total debt against $66.3M cash at 2026-06-30, MATV should track high-yield credit conditions and small-cap risk appetite more closely than it tracks specialty-chemical fundamentals. A widening in HY spreads compresses the deleveraging multiple directly.\n- Segment read-across: SAS (tapes, labels, adhesive solutions) is levered to packaging, construction and consumer durables volumes; FAM (filtration media and advanced films) is levered to transportation and industrial filtration demand. Prints from adhesive and label peers (Avery Dennison, H.B. Fuller) and filtration-media peers set the volume expectation MATV is measured against.\n- Currency and portfolio: reported growth of 1.2% came in below organic growth of 1.7% in Q2 2026 — the inference is a currency or portfolio drag, and the composition is verifiable in the 10-Q rather than assumed here.\n- Structural discontinuity in the comp set: the Engineered Papers business was sold for $620M to Evergreen Hill Enterprise, producing a $176.3M gain on sale, so pre-2024 revenue, margin and leverage history describes a different company from the two-segment entity reporting today.",
  "first_seen": "2026-08-07",
  "last_analyzed": "2026-08-09T08:10:07+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}